logo
Plus   Neg
Share
Email

Rockwell Collins Q3 Profit From Cont. Ops. Rises - Quick Facts

Rockwell Collins, Inc. (COL) reported third-quarter income from continuing operations of $163 million or $1.19 per share, compared to $161 million or $1.18 per share, in the third quarter of last year. Total earnings per share was $1.15, compared to $1.20.

On average, 19 analysts polled by Thomson Reuters expected the company to report profit per share of $1.17 for the quarter. Analysts' estimates typically exclude special items.

Total sales were $1.26 billion, an increase of 12% from $1.13 billion in the same period in 2013, primarily due to the acquisition of ARINC. Analysts expected revenue of $1.30 billion for the quarter.

The company also announced it entered into an agreement to sell its satellite communications systems business formerly known as Datapath, Inc., which designs, manufactures and services ground-based satellite communication systems primarily for military customers.

The company updated its fiscal year 2014 outlook from continuing operations due to the pending sale of Datapath and to narrow the ranges from the previous financial guidance.

Total sales are expected to be between $4.90 billion to $4.95 billion, compared to prior guidance range of $4.95 billion to $5.05 billion. Earnings per share is expected to be between $4.45 and $4.55, compared to previous guidance of $4.40 to $4.55. Analysts expect the company to report full year profit per share $4.50 on revenue of $5.04 billion.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
An administrative law judge has ruled that Minnesota regulators should approve Enbridge Inc.'s proposal to replace its aging Line 3 crude oil pipeline only if the company follows the existing route and not its preferred route. Enbridge has applied to replace its Line 3 pipeline from Alberta with new pipe along its existing route. In Minnesota, the planned route deviates from the existing route. CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health...
RELATED NEWS
Trade COL now with 
Follow RTT